High Affinity cAMP-Specific Phosphodiesterase VII: A Promising Drug Target and Biomarker

Target Name: High affinity cAMP-specif

NCBI ID: P16679

High affinity cAMP-specif

Other Name(s): Phosphodiesterase VII | PDEVII | PDE7

High Affinity cAMP-Specific Phosphodiesterase VII: A Promising Drug Target and Biomarker

Phosphodiesterase VII (PD-7) is a key enzyme in cell signaling pathways, and its dysfunction has been implicated in numerous diseases, including cancer, neurodegenerative disorders, and chronic pain. High affinity cAMP-specific PD-7 has been identified as a promising drug target and biomarker due to its unique mechanism of action and its potential to modulate cellular signaling pathways. In this article, we will explore the biology of high affinity cAMP-specific PD-7 and its potential as a drug target.

The Role of Phosphodiesterase VII in Cell signaling pathways

Phosphodiesterase VII is an enzyme that plays a critical role in the regulation of cellular signaling pathways. It is involved in the breakdown of cAMP, which is a key signaling molecule that regulates various cellular processes, including cell growth, differentiation, and inflammation. The breakdown of cAMP by PD-7 results in the formation of inactive AMP, which is then removed by another enzyme, the cGMP-protein phosphatase (PMA).

The regulation of cAMP is critical for the maintenance of cellular homeostasis and for the regulation of various cellular processes. High affinity cAMP-specific PD-7 has been shown to play a unique role in the regulation of cellular signaling pathways. It has been shown to increase the affinity for cAMP, allowing it to bind more effectively to its substrate, PD-4, and to enhance the rate of cAMP breakdown.

The Potential of High Affinity cAMP-Specific PD-7 as a Drug Target

The identification of high affinity cAMP-specific PD-7 as a potential drug target is based on its unique mechanism of action and its potential to modulate cellular signaling pathways. High affinity cAMP-specific PD-7 has been shown to be a more stable binding partner for PD-4 compared to its natural substrate, cGMP. This stability allows for the formation of more cAMP, which can activate various cellular signaling pathways, including the cAMP-protein kinase (CRE), which is involved in cell growth and survival.

The potential of high affinity cAMP-specific PD-7 as a drug target is further enhanced by its expression in various tissues and organs, including the brain, where it has been shown to be involved in the regulation of neurotransmitter release and neuroinflammation. Additionally, high affinity cAMP-specific PD-7 has been shown to be involved in the regulation of pain perception and neurodegenerative disorders, making it an attractive target for the development of new treatments for these conditions.

The Potential of High Affinity cAMP-Specific PD-7 as a Biomarker

High affinity cAMP-specific PD-7 has also been shown to be a potential biomarker for various diseases, including cancer and neurodegenerative disorders. The regulation of cAMP by PD-7 has been shown to be altered in various diseases, including cancer, neurodegenerative disorders, and chronic pain.

For example, high affinity cAMP-specific PD-7 has been shown to be decreased in various types of cancer, including breast, ovarian, and colorectal cancer. This decrease in PD-7 activity has been shown to contribute to the development and progression of these diseases. Additionally, high affinity cAMP-specific PD-7 has been shown to be involved in the regulation of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

The potential of high affinity cAMP-specific PD-7 as a biomarker is further enhanced by its potential to be used as a therapeutic agent. For example, studies have shown that inhibitors of high affinity cAMP-specific PD-7 have been shown to be effective in treating

Protein Name: High Affinity CAMP-specific 3',5'-cyclic Phosphodiesterase 7 (nonspecified Protein)

The "High affinity cAMP-specif Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about High affinity cAMP-specif comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets